Lisa A. Carey, MD, on Pembrolizumab in Advanced Triple-Negative Breast Cancer
2014 San Antonio Breast Cancer SymposiumLisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.
Related Videos
Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data
Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and ph...
Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial
Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05,
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials: • B-40, the only study to combine neoadjuvant and adjuvant chemoth...
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials
Gunter von Minckwitz, MD, on the Phase III ICE Trial
Gunter von Minckwitz, MD, of the University of Frankfurt, offers his thoughts on abstract S3-04,
Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:
